The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kosakyan S.M.

Helmholtz National Medical Research Center of Eye Diseases

Robustova O.V.

Helmholtz National Medical Research Center of Eye Diseases

Bessmertny A.M.

Helmholtz National Medical Research Center of Eye Diseases

Kalinina O.M.

Helmholtz National Medical Research Center of Eye Diseases

Vasilenkova L.V.

Helmholtz National Medical Research Center of Eye Diseases

Effectiveness and safety of drug combination therapy in patients with advanced primary open-angle glaucoma

Authors:

Kosakyan S.M., Robustova O.V., Bessmertny A.M., Kalinina O.M., Vasilenkova L.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(5): 96‑102

DOI: 10.17116/oftalma202013605196

Views: 2223

Downloaded: 64

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kosakyan SM, Robustova OV, Bessmertny AM, Kalinina OM, Vasilenkova LV. Effectiveness and safety of drug combination therapy in patients with advanced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2020;136(5):96‑102. (In Russ.)
https://doi.org/10.17116/oftalma202013605196

Подписка 2025 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Clinical outcomes of laser acti­vation of hydraulic permeability of the sclera in the treatment of adva­nced glaucoma. Russian Annals of Ophthalmology. 2023;(6):19-25
The effect of phacoemulsification of age-related cata­ract on intraocular pressure and iridocorneal angle para­meters in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2023;(6):60-68
The asso­ciation between myopia and glaucoma. Russian Annals of Ophthalmology. 2024;(1):93-98
Changes in intraocular pressure and biometric para­meters of the ante­rior segment of the eye after intravitreal inje­ctions. Russian Annals of Ophthalmology. 2024;(2-2):7-15
Role of point-by-point light sensitivity in the asse­ssment of glaucoma progression. Russian Annals of Ophthalmology. 2024;(2-2):34-42
Influence of corneal curvature and peri­pheral thickness on tono­metry readings. Russian Annals of Ophthalmology. 2024;(2-2):43-50
Topi­cal application of hypo­tensive drugs for the prevention of intraocular pressure elevation after intravitreal inje­ctions of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;(2-2):73-79
Mino­xidil-induced ophthalmic hype­rtension (case report). Russian Annals of Ophthalmology. 2024;(2-2):90-93
Thre­sholds and variability of reti­nal light sensitivity in each point of the examined visual field. Russian Annals of Ophthalmology. 2024;(2-2):116-122
Factors affe­cting the hypo­tensive effect of sele­ctive laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(2):54-62

PURPOSE

To study the hypotensive effectiveness and safety of Bimoptic Plus (bimatoprost 0.03% + timolol 0.5%) in patients with developed primary open-angle glaucoma (POAG).

MATERIAL AND METHODS

The study included 30 patients aged 57 to 72 years (45 eyes). The 1st group included 15 patients (24 eyes) who were first diagnosed with developed glaucoma with moderately elevated and high intraocular pressure (IOP) and prescribed the drug as starting therapy. Patients of the 2nd group (15 patients, 21 eyes) were prescribed Bimoptic Plus with insufficient effectiveness of monotherapy with prostaglandin analogues. The follow-up period was 6 months.

RESULTS

The study was completed by 26 patients (41 eyes). Three patients (10%) has stopped using Bimoptic Plus due to side effects, one (3.3%) — due to insufficient hypotensive effect. In the 1st group, the maximum IOP decrease was recorded at the 1st month of the study and amounted to 8.34±1.47 mm Hg (32.2%) compared to baseline, while after 2 weeks, 3 and 6 months it decreased to 8.1±1.52 mm Hg (31.3%), 7.93±1.35 mm Hg (30.6%) and 7.9±1.42 mm Hg (30.5%), respectively. In patients of the 2nd group, additional IOP decrease after 2 weeks, 1, 3, and 6 months from the start of therapy was 4.68±1.24 mm Hg (20.5%), 4.94±1.18 mm Hg (21.7%), 4.55±1.23 mm Hg (20%), 4.5±1.26 mm Hg (19.7%), respectively.

CONCLUSION

Bimoptic Plus effectively reduces the IOP level and has the least amount adverse reactions. It can be recommended for wide use in the treatment of patients with POAG.

Keywords:

glaucoma
intraocular pressure
fixed combination of bimatoprost and timolol
bimoptic plus

Authors:

Kosakyan S.M.

Helmholtz National Medical Research Center of Eye Diseases

Robustova O.V.

Helmholtz National Medical Research Center of Eye Diseases

Bessmertny A.M.

Helmholtz National Medical Research Center of Eye Diseases

Kalinina O.M.

Helmholtz National Medical Research Center of Eye Diseases

Vasilenkova L.V.

Helmholtz National Medical Research Center of Eye Diseases

Received:

18.04.2020

Accepted:

30.04.2020

List of references:

  1. Natsional’noye rukovodstvo po glaukome [National Guide to Glaucoma]. Eds. Egorov E.A., Erichev V.P. M. 2019. (In Russ.).
  2. Astahov YuS, Nechiporenko PA. Analogues of prostaglandins: past, present, future. Oftal’mologicheskie vedomosti. 2017;10(1):40-52. (In Russ.). https://doi.org/10.17816/OV10140-52
  3. Terminology and Guidelines for Glaucoma. 4th ed. 2014.
  4. Dzhumataeva ZA. Prostaglandin analogues in glaucoma treatment. Vestnik oftal’mologii. 2016;4:62-67. (In Russ.). https://doi.org/10.17116/oftalma2016132462-67
  5. Gazizova IR, Zainullina SR, Martynova EB. Effectiveness and safety of additive therapy and monotherapy of glaucoma with prostamides. Oftal’mologiya = Ophthalmology in Russia. 2019;16(3):366-370. (In Russ.). https://doi.org/10.18008/1816-5095-2019-3-366-370
  6. Antonov AA, Agadzhanyan TM, Vitkov AA. Hypotensive efficacy of bimatoprost in the treatment of primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2019;18(1):95-104. (In Russ.). https://doi.org/10.25700/NJG.2019.01.11
  7. Brandt JD, Cantor LB, Katz LJ, et al. Early Manifest Glaucoma Trial Group Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3):211-216.  https://doi.org/10.1097/IJG.0b013e3181507313
  8. Feuerhake C, Buchholz P, Kimmich F. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Curr Med Res Opin. 2009;25(4):1037-1043. https://doi.org/10.1185/03007990902816947
  9. Lewis RA, Gross RL, Sall KN, et al. Ganfort Investigators Group II The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19(6): 424-426.  https://doi.org/10.1097/IJG.0b013e3181bdb586
  10. Centofanti M, Oddone F, Gandolfi S, et al. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol. 2010;150(4):575-580.  https://doi.org/10.1016/j.ajo.2010.05.003
  11. Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009;19(1):66-71.  https://doi.org/10.1177/112067210901900110
  12. Macky TA. Bimatoprost/timolol versus travoprost/timolol fixed combinations in an Egyptian population: a hospital-based prospective randomized study. J Glaucoma. 2014;23(8):561-566.  https://doi.org/10.1097/IJG.0b013e3182867be3
  13. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye. 2009; 23(4):810-818.  https://doi.org/10.1038/eye.2008.148
  14. Jothi R, Ismail AM, Senthamarai R, Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol. 2010;42(6): 362-365.  https://doi.org/10.4103/0253-7613.71917
  15. Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079. https://doi.org/10.1371/journal.pone.0045079

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.